Written and maintained by CASRAI Editorial Board
Last updated
Blood Advances is an open-access hematology journal published by the American Society of Hematology (ASH). It began in November 2016, covers basic, translational and clinical hematology, and has ISSN 2473-9537 (electronic) and 2473-9529 (print). This page is a fact sheet for researchers deciding whether and how to cite or consider the journal; it states what ASH and the U.S. National Library of Medicine (NLM) say, with the date each was read (7 November 2026).
What is Blood Advances?
Blood Advances is a peer-reviewed journal of the American Society of Hematology. ASH describes it as an open-access journal covering all areas of hematology, including original research and community resources such as ASH Clinical Guidelines. The NLM Catalog record (ID 101698425, last revised 11 May 2026) gives the title as “Blood advances”, the MEDLINE abbreviation as Blood Adv, the first issue as Volume 1, Number 1 dated 29 November 2016, and the format as an online resource also issued in print. For the discipline itself, see what is hematology.
Who publishes it and what does it cover?
The issuing body is the American Society of Hematology, Washington, DC. NLM records the scope as an international forum for original articles describing basic laboratory, translational and clinical investigations in hematology, covering disorders of leukocytes (benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology and hematologic oncology. NLM lists the frequency as semimonthly, meaning twice a month.
ASH states that Blood Advances publishes more peer-reviewed hematology research than any other scientific journal. That is the publisher’s own claim and is attributed here rather than independently measured.
| Item | Value | Source (read 2026-11-07) |
|---|---|---|
| Publisher | American Society of Hematology | NLM Catalog |
| First issue | Vol 1 no 1, 29 November 2016 | NLM Catalog |
| ISSN (electronic / print) | 2473-9537 / 2473-9529 | NLM Catalog |
| Frequency | Semimonthly | NLM Catalog |
| Access model | Open access | ASH publications page |
| Journal abbreviation | Blood Adv | NLM Catalog |
The ISSN is useful when checking that a reference or a database record points to the right journal rather than to the flagship Blood.
Where is Blood Advances indexed?
According to the NLM Catalog, Blood Advances is currently indexed in MEDLINE (full indexing, from Volume 1 Number 4, January 2017) and in PubMed (from Volume 1 Number 1, 2016), and is listed in PubMed Central (PMC). The distinction matters when citing or searching: PubMed is the broader search interface, MEDLINE is the curated subset with subject indexing, and PMC is the full-text archive. The MEDLINE start date (January 2017) is later than the first issue, so the earliest issues are findable in PubMed but fall before MEDLINE’s full indexing start.
What is the impact factor of Blood Advances?
ASH’s publications page states a 2025 Impact Factor of 7.7 for Blood Advances, compared with 23.9 for the flagship journal Blood. Both figures are ASH-stated, read on 7 November 2026. The Journal Impact Factor is calculated by Clarivate and released in Journal Citation Reports; for how the number is built and what it does and does not say about an individual article, see journal impact factor. For the flagship, see Blood impact factor.
Is Blood Advances a Q1 journal?
Quartile is not a property that ASH or NLM publishes. A quartile is derived from a journal’s rank within a subject category in Journal Citation Reports (or a similar index), so it depends on the category, the year and the database used. To answer the question for a given year, look up the journal in the hematology category listing of Journal Citation Reports and read its rank directly rather than relying on a third-party label.
Where do I find the journal?
The journal home is at ashpublications.org/bloodadvances. The site carries the current issue and archives; look for the sign-in link on the journal’s home page when you need the author or reviewer area. Author instructions, article-processing charges and waiver terms are set by ASH and can change, so take them from the journal’s own author pages at the time you submit rather than from any summary, including this one.
Strengths and limits
Strengths
- Backed by a single society publisher whose name and open-access status are consistent across ASH and NLM descriptions.
- Indexed in PubMed and MEDLINE, with a PMC listing, so articles are discoverable in the standard biomedical search tools.
- Open access, so the full text is available without a subscription (per ASH).
- Broad hematology scope, from benign disorders to hematologic oncology.
Limits
- It is a general hematology title: work in a narrow subfield may fit better in a specialist ASH sister journal (table below).
- The impact factor figure above is the publisher’s statement; verify the current value in Journal Citation Reports before using it in an evaluation.
- Open access does not by itself say what an author pays; check the journal’s author pages.
Blood Advances compared with the other ASH journals
ASH publishes several titles with similar names. The descriptions below are ASH’s own, from its publications page (read 7 November 2026). If you were looking for “Blood journal” or “Blood Neoplasia”, this table separates them.
| Journal | ASH’s description | Access / impact factor as stated by ASH |
|---|---|---|
| Blood | ASH’s flagship journal | Impact Factor 23.9 |
| Blood Advances | All areas of hematology, including original research and community resources such as ASH Clinical Guidelines | Open access; Impact Factor 7.7 |
| Blood Global Hematology | Global hematology issues and underrepresented regions | Open access |
| Blood Immunology & Cellular Therapy | Immunotherapies | Open access |
| Blood Neoplasia | Hematologic malignancies | Open access |
| Blood Red Cells & Iron | Erythroid disorders | Open access |
| Blood Vessels, Thrombosis & Hemostasis | Hemostasis and vascular topics | Open access |
ASH also publishes news titles (The Hematologist, ASH Clinical News, ASH News Daily), which are not research journals.
FAQ
What are Blood Advances?
“Blood Advances” is a single journal, not a plural: an open-access hematology journal of the American Society of Hematology, first issued on 29 November 2016.
Is Blood a Q1 journal?
ASH states an Impact Factor of 23.9 for Blood, but quartile is assigned by category rank in Journal Citation Reports, not by ASH. Check the hematology category listing for the year you need. The same applies to Blood Advances.
What is the impact factor of the journal Blood Advances?
ASH states a 2025 Impact Factor of 7.7 (publications page, read 7 November 2026). The official value is held by Clarivate in Journal Citation Reports.
What is the best hematology journal?
No source used here ranks hematology journals as “best”; the answer depends on whether you need reach, subfield fit, access model or indexing. Compare candidates on the objective fields above (scope, indexing, access) and on category rank in Journal Citation Reports, then match the journal to your article’s subject.
Sources
- NLM Catalog, “Blood advances”, record 101698425, revised 11 May 2026, read 7 November 2026: ncbi.nlm.nih.gov/nlmcatalog/101698425
- American Society of Hematology, Publications, hematology.org/publications, read 7 November 2026.
- Blood Advances journal home: ashpublications.org/bloodadvances
